drugset / Trial / NCT01424826

The Effect of Intermittent Rifampicin on Raltegravir

NCT01424826

NaSingle-groupOpen-labelTreatment

Summary

This study seeks to address the question of whether intermittent dosing of rifampicin influences the pharmacokinetics of raltegravir when co-administered. This study aims to look at what happens when rifampicin is taken 3 times a week with the standard dose and an increased dose of raltegravir. This is to find out the best dose of raltegravir to take when taking rifampicin 3 times a week. The study will be conducted in 18 healthy volunteers.

Timeline

Start
2012-01
Primary completion
2013-06
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified 400 mg
Subject Raltegravir Other / unclassified 800 mg
Subject Rifampin Small molecule 600 mg
Subject Rifampin Small molecule 900 mg